Yesterday we presented at the XXX Congress of the Spanish Diabetes Society, which is being held these days in Seville, interesting preliminary results on the beneficial effects of the synthetic cannabinoid Abn-
CBD in animal models of type 1 diabetes. Specifically, this compound seems to counteract the insulitis, (inflammation and infiltration of immune cells in the pancreatic islets that triggers the death of insulin-producing cells) as well as improve the inflammatory and oxidative profile at both the systemic and
pancreatic levels.
